This page shows the latest Inebilizumab news and features for those working in and with pharma, biotech and healthcare.
Meanwhile, another emerging rival in the NMOSD category is Viela Bio, whose inebilizumab was filed for approval with the FDA earlier this year. ... Viela thinks inebilizumab has a dosing advantage over both Soliris and satralizumab as it can be
Another contender comes from Viela Bio, inebilizumab, which was filed for approval with the FDA earlier this month. ... Viela thinks inebilizumab has a dosing advantage over both these rivals as it can be delivered just twice a year.
The money raised in the IPO will give the Maryland-based biotech the financial muscle it needs to start building the commercial platform for its lead drug inebilizumab, which has just ... Inebilizumab is an anti-CD19 antibody developed initially to treat
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...